Aligos Therapeutics Unveils Promising Results at APASL 2025 Conference
Aligos Therapeutics, Inc. (NASDAQ: ALGS), a pioneering clinical stage biopharmaceutical company, continues to push the boundaries in the fight against liver and viral diseases. Recently, the company showcased significant progress at the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL) 2025, held in Beijing. During this event, Aligos presented positive data from three compelling oral presentations, highlighting the advancements made in their drug development.
Groundbreaking Data on ALG-000184
At the conference, researchers discussed the promising outcomes from their Phase 1 study of ALG-000184, a potential breakthrough treatment for chronic hepatitis B. With results extending to 96 weeks, the data showed remarkable reductions in important HBV markers, which may indicate the drug's potential as a first-line therapy.
Dr. Lawrence Blatt, the CEO of Aligos, expressed optimism, stating, "We are excited to share these groundbreaking preliminary findings that indicate ALG-000184 demonstrates first-/best-in-class antiviral activity, offering hope to those with chronic hepatitis B." The study indicated that all subjects treated with a daily dose of 300 mg of ALG-000184 achieved ongoing HBV DNA suppression — a significant milestone.
Comprehensive Results from the Trial
The trial included various subjects, revealing that all HBeAg-positive patients maintained viral suppression without developing resistance to the treatment. Furthermore, multi-log reductions across key HBV markers were noted, showcasing the drug's effectiveness and safety. This strengthens the proposition of ALG-000184 becoming a cornerstone therapy in chronic hepatitis B treatment.
Exploring ALG-055009 for Metabolic Dysfunction
Another key highlight from the presentations was the Phase 2a study of ALG-055009, focused on Metabolic Dysfunction-Associated Steatohepatitis (MASH). Initial data indicate that this new THR-? agonist is not only well-tolerated but also yields considerable decreases in liver fat content, marking a potential therapy for this complex condition.
Data from the trial showed that after 12 weeks of treatment, subjects experienced substantial liver fat reductions — up to 46.2% as measured by MRI-PDFF. This is particularly promising, offering new hope for patients suffering from this liver condition. Importantly, among subjects on stable GLP-1 agonist therapy, ALG-055009 displayed an outstanding profile, significantly lowering liver fat in treated individuals.
Data Presentation Details
The presentations showcased by Aligos were meticulously detailed, providing insight into the profound impact of their therapies. Each presentation pinpointed the need for innovative treatments in the realm of liver diseases.
For instance, Ed Gane, a prominent hepatologist from New Zealand, highlighted ALG-000184’s remarkable efficacy in untreated HBeAg-negative patients. Simultaneously, Professor Man-Fung Yuen from Hong Kong presented data showcasing the viral suppression rates of ALG-000184 among HBeAg-positive subjects.
About Aligos Therapeutics
Aligos Therapeutics is firmly dedicated to enhancing patient outcomes through the development of best-in-class therapies. The company prides itself on a science-driven approach to navigate the complexities of liver and viral diseases, leveraging their comprehensive R&D expertise to tackle unmet medical needs effectively.
In a landscape where chronic hepatitis and metabolic liver diseases present considerable challenges, Aligos remains committed to innovation and excellence. Their ongoing clinical trials are paving the way for new therapies that could transform the treatment landscape, providing hope to many.
Frequently Asked Questions
What is ALG-000184 used for?
ALG-000184 is a therapeutic candidate targeting chronic hepatitis B, aiming to reduce viral loads and achieve sustained suppression of the virus.
How does ALG-055009 work?
ALG-055009 is a THR-? agonist designed to reduce liver fat content, showing promise for treating Metabolic Dysfunction-Associated Steatohepatitis (MASH).
What were the results from the Phase 1 study?
The Phase 1 study of ALG-000184 indicated that all subjects had significant reductions in HBV DNA, with no resistance observed throughout the treatment period.
Who presented during the APASL conference?
Key presentations were made by leading researchers, including Ed Gane and Professor Man-Fung Yuen, both experts in hepatology.
What is the mission of Aligos Therapeutics?
Aligos Therapeutics is focused on developing innovative therapies for liver and viral diseases, striving to improve patient outcomes through scientific advancements.
